Review



ex vivo metap2 assay development  (Exosome Diagnostics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Exosome Diagnostics ex vivo metap2 assay development
    FIGURE 1 <t>METAP2</t> inhibition measured in whole blood following
    Ex Vivo Metap2 Assay Development, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ex vivo metap2 assay development/product/Exosome Diagnostics
    Average 86 stars, based on 1 article reviews
    ex vivo metap2 assay development - by Bioz Stars, 2026-05
    86/100 stars

    Images

    1) Product Images from "A phase 1 safety study of evexomostat (SDX-7320) in late-stage cancer patients: an anti-angiogenic, insulin-sensitizing drug conjugate targeting MetAP2"

    Article Title: A phase 1 safety study of evexomostat (SDX-7320) in late-stage cancer patients: an anti-angiogenic, insulin-sensitizing drug conjugate targeting MetAP2

    Journal: Cancer Research Communications

    doi: 10.1158/2767-9764.crc-24-0627

    FIGURE 1 METAP2 inhibition measured in whole blood following
    Figure Legend Snippet: FIGURE 1 METAP2 inhibition measured in whole blood following

    Techniques Used: Inhibition



    Similar Products

    ex vivo metap2 assay development  (Exosome Diagnostics)
    86
    Exosome Diagnostics ex vivo metap2 assay development
    FIGURE 1 <t>METAP2</t> inhibition measured in whole blood following
    Ex Vivo Metap2 Assay Development, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ex vivo metap2 assay development/product/Exosome Diagnostics
    Average 86 stars, based on 1 article reviews
    ex vivo metap2 assay development - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 1 METAP2 inhibition measured in whole blood following

    Journal: Cancer Research Communications

    Article Title: A phase 1 safety study of evexomostat (SDX-7320) in late-stage cancer patients: an anti-angiogenic, insulin-sensitizing drug conjugate targeting MetAP2

    doi: 10.1158/2767-9764.crc-24-0627

    Figure Lengend Snippet: FIGURE 1 METAP2 inhibition measured in whole blood following

    Article Snippet: The authors acknowledge the contributions of Dr. Melissa Johnson (Sarah Cannon Research Institute), Dr. Johanna C. Bendell (currently, Roche) and Dr. Jasgit Sachdev (currently, Ideaya Biosciences) for patient enrollment and Joeseph Johnson (Exosome Diagnostics) for ex vivo METAP2 assay development.

    Techniques: Inhibition